The trials, called ACTIVcampaign-pages/cd3/campaign-pages/cd3/-2 and ACTIV-3, will look at U.S. drugmaker Eli Lilly’s experimental treatment known as LY-CoV555, which is being developed in partnership with Canadian biotech firm AbCellera.
Full coverage on CNBC.